Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin | Zendy

Christine M. Sanfilippo | Zendy; Christine K. Hesje | Zendy; Wolfgang Haas | Zendy; Timothy W. Morris | Zendy

Open Access

Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in <i>Staphylococcus aureus</i> Have Less Effect on the Antibacterial Activity of Besifloxacin

Author(s) -

Christine M. Sanfilippo,

Christine K. Hesje,

Wolfgang Haas,

Timothy W. Morris

Publication year - 2011

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000330858

Subject(s) - dna gyrase , topoisomerase iv , levofloxacin , gatifloxacin , ciprofloxacin , quinolone , microbiology and biotechnology , moxifloxacin , staphylococcus aureus , ofloxacin , antibacterial agent , biology , antibiotics , escherichia coli , genetics , gene , bacteria

The impact of mutations in DNA gyrase and topoisomerase IV on minimum inhibitory concentrations (MICs) was investigated to better understand why besifloxacin has a higher potency against Staphylococcus aureus when compared to other fluoroquinolones, which was especially pronounced against ciprofloxacin-resistant isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research